title: Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis.
abstract: Although the acute renal toxicity of cisplatin has been well documented, long-term follow-up studies in cisplatin-treated children are scanty. We have evaluated the incidence and characteristics of both acute and chronic nephrotoxicity in 22 children (median age 8 years) treated with cisplatin as part of different chemotherapeutic protocols. All patients exhibited a significant and progressive decrease in plasma magnesium (Mg) values soon after cisplatin administration. Magnesiuria also increased immediately after therapy. Hypomagnesemia (plasma Mg < 1.4 mg/dl) occurred in 10 patients and it was dose-dependent. Minimal and mean cumulated doses inducing hypomagnesemia were 300 and 500 mg/m2, respectively. In 18 children we followed renal function prospectively for a mean time of 2.3 years after arrest of cisplatin therapy. Chronic hypomagnesemia and moderate elevation of plasma creatinine were observed in 6 children, hypocalciuria in 5 children, and hypokalemia in 1 child. Presence of hypomagnesemia was unrelated to the total dose received or the time elapsed since cisplatin therapy. Renal function studies, performed in the 6 children with chronic hypomagnesemia, revealed different degrees of impairment in Mg reabsorption. The functional characteristics of chronic cisplatin nephrotoxicity found in the present series-contrary to prior reports-are not comparable to those present in the inherited Gitelman's syndrome.
authors.affiliation: Division of Nephrology, Hospital de Cruces, Bilbao, Spain.
authors.forename: G
authors.initials: G
authors.lastname: Ariceta
authors.forename: J
authors.initials: J
authors.lastname: Rodriguez-Soriano
authors.forename: A
authors.initials: A
authors.lastname: Vallo
authors.forename: A
authors.initials: A
authors.lastname: Navajas
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006706:Homeostasis / Q000187:drug effects*; D006801:Humans; D007223:Infant; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology*; D008274:Magnesium / Q000378:metabolism*; D008297:Male; D011446:Prospective Studies
chemical_list: D000970:Antineoplastic Agents; D008274:Magnesium; D002945:Cisplatin